(Q35609717)

9 August 2017

1 reference

title

Histone deacetylase inhibitors in clinical development (English)

1 reference

9 August 2017

Roberto R Rosato

1

1 reference

PubMed ID

14680450

9 August 2017

Steven Grant

series ordinal

2

1 reference

PubMed ID

14680450

9 August 2017

language of work or name

English

0 references

publication date

1 January 2004

1 reference

Expert Opinion on Investigational Drugs

9 August 2017

1 reference

9 August 2017

13

1 reference

9 August 2017

21-38

1 reference

9 August 2017

1

1 reference

Histone deacetylase inhibitors in cancer treatment

9 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.21

Histone deacetylases as therapeutic targets in hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.21

Histone deacetylases and cancer: causes and therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.21

Histone deacetylase inhibitors: from target to clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.21

Histone acetylation and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.21

Histone deacetylases, transcriptional control, and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.21

Histone deacetylase inhibitors in cancer therapy: is transcription the primary target?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.21

The language of covalent histone modifications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.21

Histone deacetylases (HDACs): characterization of the classical HDAC family

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.21

Histone acetylation and chromatin remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.21

The human histone deacetylase family

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.21

Histone acetyltransferases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.21

Transcriptional control at regulatory checkpoints by histone deacetylases: molecular connections between cancer and chromatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.21

Histone acetylation beyond promoters: long-range acetylation patterns in the chromatin world

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.21

Sodium butyrate inhibits histone deacetylation in cultured cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.21

Dietary fiber, vegetables, and colon cancer: critical review and meta-analyses of the epidemiologic evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.21

Histone acetylation and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.21

Novel mutual prodrug of retinoic and butyric acids with enhanced anticancer activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.21

The histone deacetylase inhibitor AN-9 has selective toxicity to acute leukemia and drug-resistant primary leukemia and cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.21

Activity of pivaloyloxymethyl butyrate, a novel anticancer agent, on primary human tumor colony-forming units.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.21

Sodium phenylacetate enhances the inhibitory effect of dextran derivative on breast cancer cell growth in vitro and in nude mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.21

Phenylbutyrate attenuates the expression of Bcl-X(L), DNA-PK, caveolin-1, and VEGF in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.21

Exposure to a deuterated analogue of phenylbutyrate retards S-phase progression in HT-29 colon cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.21

Phenylbutyrate inhibits the invasive properties of prostate and breast cancer cell lines in the sea urchin embryo basement membrane invasion assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.21

Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.21

Valproic acid increases the stimulatory effect of estrogens on proliferation of human endometrial adenocarcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.21

Chronic oral administration of CI-994: a phase 1 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.21

Phase I study of oral CI-994 in combination with gemcitabine in treatment of patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.21

Synthesis and histone deacetylase inhibitory activity of new benzamide derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.21

A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.21

Effects of FK228, a novel histone deacetylase inhibitor, on human lymphoma U-937 cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.21

Histone deacetylase inhibitor FK228 inhibits tumor angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.21

Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.21

Apicidin: a novel antiprotozoal agent that inhibits parasite histone deacetylase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.21

Induction of fetal hemoglobin synthesis by valproate: modulation of MAP kinase pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.21

Histone deacetylase inhibitor trichostatin A induces cell-cycle arrest/apoptosis and hepatocyte differentiation in human hepatoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.21

Second generation hybrid polar compounds are potent inducers of transformed cell differentiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.21

Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.21

Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.21

The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.21

Susceptibility of multidrug resistance tumor cells to apoptosis induction by histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.21

The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.21

NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.21

Anti-tumour activity in vitro and in vivo of selective differentiating agents containing hydroxamate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.21

Histone deacetylase inhibitors trigger a G2 checkpoint in normal cells that is defective in tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.21

Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.21

Retinoblastoma protein recruits histone deacetylase to repress transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.21

Retinoblastoma protein represses transcription by recruiting a histone deacetylase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.21

Sodium butyrate induces G2 arrest in the human breast cancer cells MDA-MB-231 and renders them competent for DNA rereplication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.21

WAF1, a potential mediator of p53 tumor suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.21

Paclitaxel-induced apoptosis in BJAB cells proceeds via a death receptor-independent, caspases-3/-8-driven mitochondrial amplification loop

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.21

Apicidin, a histone deacetylase inhibitor, induces apoptosis and Fas/Fas ligand expression in human acute promyelocytic leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.21

Role of caspases, Bid, and p53 in the apoptotic response triggered by histone deacetylase inhibitors trichostatin-A (TSA) and suberoylanilide hydroxamic acid (SAHA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.21

p21-induced cycle arrest in G1 protects cells from apoptosis induced by UV-irradiation or RNA polymerase II blockage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.21

Constitutive hyperexpression of p21(WAF1) in human U266 myeloma cells blocks the lethal signaling induced by oxidative stress but not by Fas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.21

bcl-2 and bak may play a pivotal role in sodium butyrate-induced apoptosis in colonic epithelial cells; however overexpression of bcl-2 does not protect against bak-mediated apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.21

Histone deacetylase inhibitors such as sodium butyrate and trichostatin A induce apoptosis through an increase of the bcl-2-related protein Bad.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.21

Histone deacetylase inhibitor downregulation of bcl-xl gene expression leads to apoptotic cell death in mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.21

Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-FLIP protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.21

Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.21

Antitumor efficacy of FK228, a novel histone deacetylase inhibitor, depends on the effect on expression of angiogenesis factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.21

Inhibition of hypoxia-induced angiogenesis by FK228, a specific histone deacetylase inhibitor, via suppression of HIF-1alpha activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.21

Histone deacetylase inhibitors such as sodium butyrate and trichostatin A inhibit vascular endothelial growth factor (VEGF) secretion from human glioblastoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.21

The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.21

Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.21

DNA methylation and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.21

Worms gang up on bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.21

Reactivating the expression of methylation silenced genes in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.21

The interaction of histone deacetylase inhibitors and DNA methyltransferase inhibitors in the treatment of human cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.21

Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.21

Reactivation of the silenced and imprinted alleles of ARHI is associated with increased histone H3 acetylation and decreased histone H3 lysine 9 methylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.21

Enforced expression of the c-myc oncogene inhibits cell differentiation by precluding entry into a distinct predifferentiation state in G0/G1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.21

Synergistic induction of mitochondrial damage and apoptosis in human leukemia cells by flavopiridol and the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.21

Enhancement of depsipeptide-mediated apoptosis of lung or esophageal cancer cells by flavopiridol: activation of the mitochondria-dependent death-signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.21

Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.21

Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.21

Flavopiridol in untreated or relapsed mantle-cell lymphoma: results of a phase II study of the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.21

Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.21

Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.21

Targeted removal of PML-RARalpha protein is required prior to inhibition of histone deacetylase for overcoming all-trans retinoic acid differentiation resistance in acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.21

Histone deacetylase inhibitor but not arsenic trioxide differentiates acute promyelocytic leukaemia cells with t(11;17) in combination with all-trans retinoic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.21

Frequent mutations in the ligand-binding domain of PML-RARalpha after multiple relapses of acute promyelocytic leukemia: analysis for functional relationship to response to all-trans retinoic acid and histone deacetylase inhibitors in vitro and in v

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.21

The histone deacetylase inhibitor sodium butyrate interacts synergistically with phorbol myristate acetate (PMA) to induce mitochondrial damage and apoptosis in human myeloid leukemia cells through a tumor necrosis factor-alpha-mediated process

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.21

Butyrate sensitizes human colon cancer cells to TRAIL-mediated apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.21

Inhibition of histone deacetylase activity enhances Fas receptor-mediated apoptosis in leukemic lymphoblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.21

Inhibition of PI-3 kinase sensitizes human leukemic cells to histone deacetylase inhibitor-mediated apoptosis through p44/42 MAP kinase inactivation and abrogation of p21(CIP1/WAF1) induction rather than AKT inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.21

Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.21

Imatinib mesylate--a new oral targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.21

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.21

The proteasome: a novel target for cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.21

Proteasome inhibitors induce growth inhibition and apoptosis in myeloma cell lines and in human bone marrow myeloma cells irrespective of chromosome 13 deletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.21

Proteasome inhibitors induced caspase-dependent apoptosis and accumulation of p21WAF1/Cip1 in human immature leukemic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.21

Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.21

Bortezomib in Multiple Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.21

Phase II study of oral vinorelbine in first-line advanced breast cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.21

21 January 2018

Identifiers

DOI

10.1517/13543784.13.1.21

1 reference

9 August 2017

1 reference

PubMed ID

14680450